{"nctId":"NCT00946920","briefTitle":"A Trial of Degarelix in Patients With Prostate Cancer","startDateStruct":{"date":"2009-06"},"conditions":["Prostate Cancer"],"count":859,"armGroups":[{"label":"Degarelix 240 mg/480 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Degarelix"]},{"label":"Goserelin acetate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Goserelin acetate"]}],"interventions":[{"name":"Degarelix","otherNames":["Firmagon","FE200486"]},{"name":"Goserelin acetate","otherNames":["Zoladex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 years or older.\n* Has a histological confirmed prostate cancer Gleason graded).\n* Has a screening testosterone above 2.2 ng/mL.\n* Rising prostate-specific antigen (PSA).\n* Has Eastern Cooperative Oncology Group (ECOG) score of ≤ 2.\n* Has a life expectancy of at least one year.\n\nExclusion Criteria:\n\n* Current or previous hormone therapy.\n* Has received therapy with finasteride and dutasteride within 12 weeks and 25 weeks, respectively, prior to screening.\n* Has a history of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.\n* Has a heart insufficiency.\n* Has a previous history or presence of another malignancy, other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last five years.\n* Has a clinically significant medical condition (other than prostate cancer) including, but not limited to, renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease and alcohol or drug abuse or any other condition which may affect the patient's health or the outcome of the trial as judged by the Investigator.\n* Has received an investigational drug within the last 28 days before the Screening Visit or longer if considered to possibly influencing the outcome of the current trial.\n* Is candidate for curative therapy, i.e. radical prostatectomy or radiotherapy.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With Degarelix","description":"This co-primary outcome measure was used to demonstrate that degarelix is effective with respect to achieving and maintaining testosterone suppression to castrate levels, evaluated as the proportion of patients with testosterone suppression ≤0.5 ng/mL from Day 28 to Day 364.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Difference in Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) Between Degarelix and Goserelin","description":"This co-primary outcome measure was used to establish non-inferiority of degarelix as compared to goserelin with regard to achieving and maintaining testosterone suppression at castrate levels (≤0.5 ng/mL) from Day 3 to Day 364, using a non-inferiority margin of 5 percentage points.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Levels of Testosterone Over Time","description":"Median testosterone levels are presented as absolute values at Baseline (in Baseline measures) and after 1, 2, 3, 6 and 13 months (below). One treatment month equals 28 days.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":null},{"groupId":"OG001","value":"0.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null},{"groupId":"OG001","value":"0.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Serum Levels of Prostate-specific Antigen (PSA) Over Time","description":"Serum PSA levels are presented as mean percent change from Baseline (in Baseline measures) after 1, 2, 3, 6 and 13 months. One treatment month equals 28 days.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-77","spread":"23.7"},{"groupId":"OG001","value":"-57","spread":"45.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-89","spread":"12.6"},{"groupId":"OG001","value":"-86","spread":"18.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-90","spread":"15.4"},{"groupId":"OG001","value":"-86","spread":"58.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-90","spread":"30.5"},{"groupId":"OG001","value":"-91","spread":"18.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-82","spread":"104"},{"groupId":"OG001","value":"-77","spread":"146"}]}]}]},{"type":"SECONDARY","title":"Change in Health-related Quality of Life (HRQoL), as Measured by Short Form-36 (SF-36) Score at Month 10 and Month 13 Compared to Baseline","description":"The SF-36 is a multi-purpose, short-form health survey with only 36 questions and with a minimum score of 0 and a maximum score of 100. The higher score the better health. It yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures and a preference-based health utility index. The SF-36 has proven useful in surveys of general and specific populations, comparing the relative burden of diseases, and in differentiating the health benefits produced by a wide range of different treatments.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"11.1"},{"groupId":"OG001","value":"0.27","spread":"10.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"10.9"},{"groupId":"OG001","value":"-0.87","spread":"9.76"}]}]}]},{"type":"SECONDARY","title":"Change in International Prostate Symptom Score (IPSS) Score at Months 1, 4, 7, and 13 Compared to Baseline","description":"IPSS is used to assess severity of lower urinary tract symptoms and to monitor the progress of symptoms once treatment has been initiated. It contains 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Each question is assigned a score of 0-5 (i.e. the minimum total score is 0 and the maximum is 35). A score of \"0\" corresponds to a response of \"not at all\" for the first six symptoms and \"none\" for nocturia, and a score of 5 corresponds to a response of \"almost always\" for the first six symptoms and \"5 times or more\" for nocturia.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.06","spread":"6.27"},{"groupId":"OG001","value":"-0.21","spread":"6.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.31","spread":"6.65"},{"groupId":"OG001","value":"-1.74","spread":"6.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.47","spread":"6.94"},{"groupId":"OG001","value":"-2.45","spread":"6.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.04","spread":"7.28"},{"groupId":"OG001","value":"-1.52","spread":"6.25"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":58,"n":565},"commonTop":["Hot flush","Injection site pain","Injection site erythema","Injection site nodule","Weight increased"]}}}